Published in Biol Blood Marrow Transplant on July 15, 2010
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant (2012) 0.86
Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies. J Transl Med (2014) 0.86
New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant (2015) 0.80
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Murine leukemia induced by retroviral gene marking. Science (2002) 3.59
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science (2005) 3.58
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology (2014) 2.39
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med (2016) 2.36
Side effects of retroviral gene transfer into hematopoietic stem cells. Blood (2003) 2.35
Resistance of mature T cells to oncogene transformation. Blood (2008) 2.32
A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther (2008) 2.31
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol (2010) 2.09
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood (2006) 1.98
Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance. Leuk Lymphoma (2014) 1.94
Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther (2006) 1.83
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood (2005) 1.82
RGB marking with lentiviral vectors for multicolor clonal cell tracking. Nat Protoc (2012) 1.80
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood (2010) 1.75
RGB marking facilitates multicolor clonal cell tracking. Nat Med (2011) 1.69
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant (2010) 1.69
Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant (2009) 1.68
Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther (2004) 1.65
Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst (2012) 1.62
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Detection of virulence-associated genes not useful for discriminating between invasive and commensal Staphylococcus epidermidis strains from a bone marrow transplant unit. J Clin Microbiol (2004) 1.52
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma (2009) 1.51
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood (2006) 1.51
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol (2005) 1.48
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma (2012) 1.45
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2005) 1.45
Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny. Leuk Lymphoma (2010) 1.45
Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol Ther (2002) 1.44
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood (2007) 1.44
Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica (2008) 1.43
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood (2006) 1.41
Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. Leuk Lymphoma (2010) 1.41
Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. Leuk Lymphoma (2012) 1.40
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood (2010) 1.39
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood (2003) 1.34
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res (2009) 1.34
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34
Liver-specific gene expression in cultured human hematopoietic stem cells. Stem Cells (2003) 1.33
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 1.33
Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? Stem Cells Dev (2005) 1.30
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood (2002) 1.28
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica (2009) 1.27
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood (2013) 1.26
Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res (2009) 1.24
Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation (2006) 1.24
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol (2005) 1.23
Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells (2010) 1.23
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant (2010) 1.23
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood (2013) 1.19
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant (2008) 1.19
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 1.18
The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol (2010) 1.18
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol (2007) 1.17
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica (2008) 1.17
Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol (2003) 1.16
Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol (2013) 1.13
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol (2012) 1.12
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica (2009) 1.11
Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood (2004) 1.11
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood (2012) 1.11
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol (2011) 1.11
Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. J Immunol (2009) 1.10
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant (2011) 1.09